Amgen · 8 hours ago
Senior Scientist - PKDM (NAMs-Based Translational ADME Sciences)
South San Francisco, CA
Full-time
Hybrid
Senior Level
5+ years expAmgen is a leading biotechnology company focused on serving patients with serious illnesses. They are seeking a Senior Scientist to lead innovative research in advanced cell-based in vitro systems, specifically focusing on the design and implementation of organoid and microphysiological systems to enhance drug disposition and pharmacodynamic response predictions.
BiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Lead the development and qualification of high-fidelity, human-relevant in vitro models, including 3D cultures and microphysiological systems, to assess drug disposition, biotransformation, and pharmacodynamic effects
Design and execute experimental strategies that integrate quantitative endpoints, enabling correlation of exposure and response across NAMs and traditional models
Advance throughput and data scalability by implementing assay miniaturization, plate-based automation, and high-content imaging workflows
Apply deep cell biology expertise to refine parenchymal–stromal co-culture systems and incorporate complementary analytical endpoints to define cellular phenotype and pharmacodynamic response
Characterize responses using flow cytometry, multiplexed analytical sampling, confocal microscopy, and live-cell imaging (e.g., Incucyte)
Adopt computational tools and quantitative data pipelines to streamline analysis of complex kinetic and imaging datasets
Collaborate across disciplines to define mechanism-based PK liabilities, support dose selection hypotheses, and guide preclinical-to-clinical translation
Communicate findings clearly and effectively to inform cross-functional teams and drive data-driven decision-making in a fast-paced R&D environment
Qualification
Required
Doctorate degree in Biomedical Engineering, Pharmacology, Systems Biology, Cellular & Molecular Biology, Biophysics, or a related discipline [and relevant post-doc where applicable]
Or
Master's degree and 3 years of relevant industry experience
Or
Bachelor's degree and 5 years of relevant industry experience
Preferred
2+ years of postdoctoral or industry experience applying 3D cellular or microphysiological systems to study drug disposition or disease biology
Demonstrated experience in cell model and/or MPS device fabrication, culture, and integration with analytical readouts
Working understanding of pharmacokinetic principles for small and large molecules and of preclinical ADME processes (absorption, distribution, metabolism, and excretion)
Familiarity with bioanalytical and imaging techniques supporting quantitative in vitro pharmacology
Strong communication, data interpretation, and collaboration skills; ability to synthesize complex data into actionable insights for multidisciplinary project teams
Demonstrated ability to innovate, adapt, and deliver in a dynamic research environment
Benefits
A comprehensive employee benefits package, including a Retirement and Savings Plan with generous company contributions
Group medical, dental and vision coverage
Life and disability insurance
Flexible spending accounts
A discretionary annual bonus program, or for field sales representatives, a sales-based incentive plan
Stock-based long-term incentives
Award-winning time-off plans
Flexible work models, including remote and hybrid work arrangements, where possible
Company
Amgen
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
10001+ employees
H1B Sponsorship
Amgen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (429)
2024 (485)
2023 (485)
2022 (540)
2021 (460)
2020 (444)
Funding
Current Stage
Public CompanyTotal Funding
$28.5B2022-12-12Post Ipo Debt· $28.5B
1983-06-17IPO
Leadership Team
Robert Bradway
Chairman and Chief Executive Officer
Jay Bradner
Executive Vice President of R&D, and Chief Scientific Officer
Recent News
2025-12-30
businessweekly.co.uk
2025-12-27
Company data provided by crunchbase